Phosphine-Catalyzed [4 + 1] Annulation between α , β -Unsaturated Imines and Allylic Carbonates: Synthesis of 2-Pyrrolines

Junjun Tian, Rong Zhou, Haiyun Sun, Haibin Song, and Zhengjie He*

The State Key Laboratory of Elemento-Organic Chemistry and Department of Chemistry, Nankai University, Tianjin 300071, People's Republic of China

Supporting Information

ABSTRACT: In this report, a phosphine-catalyzed [4+1] annulation between α , β -unsaturated imines and allylic carbonates is described. This reaction represents the first realization of catalytic [4 + 1] cyclization of 1,3-azadienes with in situ formed phosphorus ylides, which provides highly efficient and diastereoselective synthesis of 2-pyrrolines.



F ive-membered nitrogen heterocycles are important and ubiquitous substructures in a vast array of natural products and biologically interesting compounds.^{1–3} Among this group of heterocycles, pyrrolines (dihydropyrroles) are not only versatile intermediates which allow ready access to pyrrolidines and pyrroles,^{4,5} but also occur in numerous natural products and therapeutic agents.^{6–8} A number of synthetic approaches toward pyrrolines therefore have been developed,^{9–12} but the majority of the existing synthetic methods are centered upon 3-pyrrolines. The synthetic methodology on 2-pyrrolines featuring an enamine skeleton is pretty underdeveloped,^{13–22} although 2-pyrrolines are very important with regard to their versatility in organic synthesis and interest in pharmaceuticals.^{1–8} Developing new and efficient synthesis of 2-pyrrolines is thus highly desirable.

The formal [4 + 1] cycloaddition of 1-aza-1,3-dienes (α,β unsaturated imines) with one-carbon units such as ylides provides a potential and straightforward protocol to construct 2-pyrroline ring system (Scheme 1).²³ The analogous syntheses of 2,3-dihydrofurans by the [4 + 1] cyclization between α_{β} unsaturated carbonyl compounds and ylides have been well documented.^{23,24} It is only recently that the syntheses of 2-pyrrolines via the [4 + 1] annulations of α_{β} -unsaturated imines have been realized with sulfur and nitrogen ylides independently by Xiao¹³ and Tang.¹⁴ It is recognized that phosphorus ylides have been rarely applied to ylide-based cyclizations, primarily due to their intrinsic reactivity preference for Wittig olefinations and the poorest leaving group ability of the phosphonium moiety compared with sulfur and nitrogen vlides.^{25,26} Consequently, the formal [4 + 1] cycloaddition of 1-aza-1,3-dienes with phosphorus ylides has not yet been realized prior to this study.

In the past decade, the nucleophilic phosphine catalysis has effected many powerful annulations of electron-deficient alkenes or alkynes with various electrophiles to construct carbo- and heterocycles.^{27,28} In principle, those phosphine-mediated annulations proceed via an addition—elimination mechanism, by which the intramolecularity of the ring-closure step can circumvent the problem arising from the poor leaving group ability of the phosphonium moiety. Even in some cases, in situ formed phosphorus ylide intermediates are presumably involved in such cyclizations.²⁸ To date, many important annulations like [3 + 2] and [4 + 2] annulations to generate five- and sixmembered nitrogen heterocycles have been developed under nucleophilic phosphine catalysis.^{29–32} Very recently, two examples of the phosphine-catalyzed [4 + 1] annulations to produce five-membered oxygen heterocycles were also reported.^{33,34} Herein, we wish to report a PPh₃-catalyzed [4 + 1] annulation between α,β -unsaturated imines and allylic carbonates which represents the first synthesis of 2-pyrrolines through a phosphorus ylide-based [4 + 1] cyclization of 1,3-azadienes (vide infra).

As part of our continuous efforts on exploring phosphorus ylide-based carbon—carbon bond forming reactions, recently we disclosed a PBu₃-catalyzed cascade [3 + 2] cyclization—allylic alkylation reaction of conjugated enones with allylic carbonates (Scheme 2).³⁵ While we attempted to extend the reaction to α , β -unsaturated imines, to our surprise, a phosphine-catalyzed [4 + 1] annulation between α , β -unsaturated imines and allylic carbonates occurred, leading to a highly efficient and diastereoselective synthesis of polysubstituted 2-pyrrolines (Scheme 2).

Our investigation was initiated with the model reaction of the chalcone-derived imine 1a and allylic carbonate 2a (Table 1). In CH₂Cl₂ solvent and at rt, several tertiary phosphines were screened as catalysts (Table 1, entries 1–6). All tested phosphines could effectively catalyze the model reaction with PPh₃ and P(4-MeO-Ph)₃ giving almost quantitative yields of 3a (entries 4 and 5). Lowering the catalyst loading of PPh₃ to 10 mol % resulted in considerable reduction of the yield (entry 7). Choosing PPh₃ as the catalyst, some common solvents were also investigated. It was found that the model reaction readily occurred in nonpolar or polar aprotic solvents, giving the product

```
Received: January 24, 2011
Published: March 09, 2011
```

Table 1. Preliminary Survey on Model Reaction Conditions^a



^{*a*} Typical conditions: under N₂ atmosphere, a mixture of **1a** (0.25 mmol), **2a** (0.3 mmol), and phosphine (0.05 mmol) in solvent (2.0 mL) was stirred at rt for 24 h. ^{*b*} Isolated yield based on **1a** and dr >20:1 by ¹H NMR of **3a**. ^{*c*} 10 mol % of PPh₃ was employed.

Scheme 1. Formal [4 + 1] Ylide Cycloaddition of 1,3-Azadienes To Generate 2-Pyrrolines



Scheme 2. Phosphine-Catalyzed Annulations of Enones or Azadienes with Allylic Carbonates



3a in good to excellent yields (entries 8–11). The results in Table 1 show that the annulation of **1a** and **2a** has good tolerance to reaction conditions.

Under the preferred conditions (PPh₃ used as the catalyst in CH₂Cl₂ at rt for 24 h), the substrate scope and limitations for the [4 + 1] annulation of unsaturated imines **1** and allylic carbonates **2** were studied (Table 2). For a wide range of aryl-substituted imines **1** (R¹, R² = aryl) with either relatively electron-poor or rich aryl groups, their corresponding [4 + 1] annulations with the allylic carbonate **2a** readily proceeded, giving 2-pyrrolines **3** in good to excellent yields (entries 1–14). Bulky alkyl-substituted allylic carbonates **2b** (R³ = *n*-Bu) and **2c** (R³ = *t*-Bu) were also examined in the reactions with the imine **1a**, readily affording the corresponding 2-pyrrolines **3o** and **3p** in high yields (entries

Table 2. Synthesis of 2-Pyrrolines 3^a

R	1 R ²	2	R ² - (Ts CO21
entry	\mathbb{R}^1 in 1	R^2 in 1	\mathbb{R}^3 in 2	yield of 3 (%), ^b dr ^c
1	Ph	Ph (1a)	Et (2a)	3 a, 99, >20:1
2	4-MeO-Ph	Ph (1b)	Et (2a)	3b , 80, >20:1
3	4-Cl-Ph	Ph (1c)	Et (2a)	3c , 85, >20:1
4	4-F-Ph	Ph (1d)	Et (2a)	3d , 97, >20:1
5	4-CF ₃ -Ph	Ph (1e)	Et (2a)	3e , 99, >20:1
6	3-NO ₂ -Ph	Ph (1f)	Et (2a)	3f , 94, >20:1
7	2-furyl	Ph (1g)	Et (2a)	3g , 87, >20:1
8	4-Cl-Ph	4-Br-Ph (1h)	Et (2a)	3h , 88, >20:1
9	4-F-Ph	4-Br-Ph (1i)	Et (2a)	3i , 84, >20:1
10	Ph	4-Cl-Ph (1j)	Et (2a)	3 <i>j</i> , 96, >20:1
11	4-CF ₃ -Ph	4-Cl-Ph (1k)	Et (2a)	3k, 89, >20:1
12	Ph	4-NO ₂ -Ph (11)	Et (2a)	31 , 95, >20:1
13	4-Cl-Ph	4-NO ₂ -Ph (1m)	Et (2a)	3m , 91, >20:1
14	4-F-Ph	4-NO ₂ -Ph (1n)	Et (2a)	3n , 84, >20:1
15	Ph	Ph (1a)	<i>n</i> -Bu (2b)	30 , 94, >20:1
16	Ph	Ph (1a)	<i>t</i> -Bu (2c)	3p , 90, >20:1
^a For details, see the Experimental Section. ^b Isolated yield based on 1.				
^c Determined by ¹ H NMR.				



Scheme 3. Synthesis of Fused Cyclic Product 3q



15 and 16). In all tested cases, the product 2-pyrroline 3 was isolated as a single diastereomer, as determined by 1 H and 13 C NMR.

Interestingly, cyclic unsaturated imine **10** was also an effective substrate (Scheme 3). Under the optimized conditions, the corresponding fused cyclic product **3q** was obtained in 83% isolated yield. However, methyl- or phenyl-substituted analogues (**2d** and **2e**) of the allylic carbonate **2a** failed in giving the expected [4 + 1] annulation products with the imine **1a**, when subjected to similar conditions (Scheme 4). In the case of **2d**, the imine substrate **1a** was inert, but the carbonate **2d** gradually decomposed into a complex mixture under the influence of PPh₃; for the phenyl-substituted allylic carbonate **2e**, a [3 + 2] annulation product **4** was obtained in 65% yield under the catalysis of more nucleophilic phosphine PhPMe₂. Similar PBu₃-catalyzed [3 + 2] annulation of the carbonate **2e** with enones was also developed in our laboratory.³⁵

The structures of compounds **3** and **4** were identified by ¹H, ¹³C NMR, and HRMS-ESI measurements. X-ray crystallographic analysis for representative compound **3a** provided unequivocal evidence for structural assignments of **3** (for details, also see the Supporting Information).

Possible mechanisms to account for the formation of **3** are depicted in Scheme 5. Presumably, the catalytic cycle is initiated with the in situ formation of the allylic phosphorus ylide **5**

Scheme 4. Investigations on Methyl- or Phenyl-Substituted Allylic Carbonates 2d and 2e



Scheme 5. Possible Mechanisms for Formation of 3



through an addition-elimination-deprotonation process.³⁶ Ylide 5 most likely undergoes the sterically favored γ -carbanion addition to 1,3-azadiene 1 (path A) leading to intermediate 6, which interconverts with intermediate 7 through a hydrogen transfer process.³⁷ Intermediate 7 furnishes 2-pyrroline 3 and regenerates the PPh₃ catalyst via an intramolecular Michael addition followed by elimination of PPh3. The failure of methyland phenyl-substituted allylic carbonates 2d and 2e to undergo the [4 + 1] annulations and the formation of the [3 + 2]annulation product 4 (Scheme 4) are in favor of the path A mechanism. Another possibility that could not be completely ruled out is the formation of the 2-pyrroline 3 through α carbanion addition of the allylic phosphorus ylide 5 to the imine 1 (path B). The resulting intermediate 8 subsequently undertakes an intramolecular S_N2 cyclization to afford 3 and release the PPh₃ catalyst (Scheme 5). Similar mechanisms were also proposed to rationalize the [4+1] annulations of 1,3-azadienes with sulfur and nitrogen ylides.^{13,14} Recently, our group reported a PPh_3 -catalyzed [2 + 2 + 2] annulation between two different alkenes, in which an intramolecular S_N2 cyclization step involving PPh3 moiety as a leaving group was also proposed."

In summary, the [4 + 1] annulation between $\alpha_{,\beta}$ -unsaturated imines and allylic carbonates has been realized under the catalysis of PPh₃, which provides highly efficient and diastereoselective synthesis of polysubstituted 2-pyrrolines. This annulation represents the first example of the formal [4 + 1] cycloaddition of 1,3azadienes and phosphorus ylides, although it is very likely that the annulation proceeds through a typical nucleophilic phosphinecatalyzed mechanism. Efforts to clarify the accurate mechanism and to exploit the use of this reaction in organic synthesis are ongoing.

EXPERIMENTAL SECTION

Unless otherwise noted, all reactions were carried out in a nitrogen atmosphere under anhydrous conditions. Column chromatography was performed on silica gel (200-300 mesh). The unsaturated imines 1 were readily prepared from the corresponding ketones according to the reported procedure.³⁹ Allylic carbonates 2 were prepared by the known method.³⁶

Preparation of N-(2-benzylidene-3,4-dihydro-2H-naphthalen-1-ylidene)-4-methylbenzenesulfonamide (10): To a solution of 4-methylbenzenesulfonamide (0.86 g, 5.0 mmol) and (E)-2benzylidene-3,4-dihydronaphthalen-1(2H)-one (1.17 g, 5.0 mmol) in CH₂Cl₂ (15 mL) were successively added Et₃N (1.01 g, 10 mmol) and TiCl₄ (0.95 g, 5.0 mmol) at 0 °C with stirring. The resulting mixture was heated at reflux overnight. After being cooled to room temperature and quenched with water (100 mL), the organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (3 × 50 mL). The combined organic phase was washed with water $(3 \times 20 \text{ mL})$ and dried over Na₂SO₄. After filtration and evaporation of solvent, the crude product was further purified by recrystallization from petroleum ether/ethyl acetate (5:1) to afford pure imine 10 (1.26 g) in 65% yield. Yellow solid; mp 132–133 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, J = 7.7 Hz, 1H), 7.94 (d, J = 8.2 Hz, 2H), 7.84 (s, 1H), 7.47-7.37 (m, 5H), 7.36-7.29 (m, 3H), 7.25 (t, J = 3.8 Hz, 1H), 7.19 (d, J = 7.7 Hz, 1H), 2.97 (s, 4H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 174.6, 142.8, 142.7, 139.7, 138.6, 135.4, 135.3, 133.4, 132.9, 129.4, 129.3, 128.6, 128.4, 128.2, 126.8, 126.7, 30.0, 27.2, 21.4; HRMS-ESI calcd for C₂₄H₂₁NO₂S $[M + Na]^+$ 410.1185, found 410.1180.

General procedure for PPh₃-catalyzed [4 + 1] annulation of 1 and 2: A mixture consisting of the imine 1 (0.25 mmol), allylic carbonate 2 (0.3 mmol), and PPh₃ (13 mg, 0.05 mmol) in CH₂Cl₂ (2 mL) was stirred at room temperature for 24 h. The reaction mixture was then concentrated on a rotary evaporator under reduced pressure and the residue was subjected to purification by column chromatography (gradient elution with petroleum ether—ethyl acetate from 20:1 to 10:1) to afford the product 3. Following the above procedure, 2-pyrrolines 3a-q were readily prepared from corresponding 1,3-azadienes 1 and allylic carbonates 2 (Table 2 and Scheme 3).

Ethyl *trans*-2-(3,5-diphenyl-1-tosyl-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3a): yield 99%; white solid; mp 153–155 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (dd, *J* = 6.6, 2.9 Hz, 2H), 7.42 (m, 3H), 7.30 (d, *J* = 8.2 Hz, 2H), 7.03 (m, 5H), 6.72 (d, *J* = 7.3 Hz, 2H), 6.50 (s, 1H), 6.26 (s, 1H), 5.27 (d, *J* = 3.4 Hz, 1H), 5.01 (d, *J* = 3.0 Hz, 1H), 4.28 (q, *J* = 7.2 Hz, 2H), 3.61 (t, *J* = 3.4 Hz, 1H), 2.40 (s, 3H), 1.30 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.8, 144.8, 143.6, 142.2, 140.9, 133.6, 132.6, 129.5, 129.1, 128.4, 128.1, 128.0, 127.9, 127.4, 126.2, 125.5, 116.0, 69.7, 61.1, 53.4, 21.5, 14.1; HRMS-ESI calcd for C₂₈H₂₇NO₄S [M + Na]⁺ 496.1553, found 496.1550.

Ethyl trans-2-(3-(4-methoxyphenyl)-5-phenyl-1-tosyl-2,3dihydro-1*H***-pyrrol-2-yl)acrylate (3b):** yield 80%; white solid; mp 154–155 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.67 (dd, *J* = 6.5, 2.9 Hz, 2H), 7.42 (m, 3H), 7.31 (d, *J* = 8.2 Hz, 2H), 7.09 (d, *J* = 8.2 Hz, 2H), 6.64 (d, *J* = 8.7 Hz, 2H), 6.56 (d, *J* = 8.7 Hz, 2H), 6.48 (s, 1H), 6.25 (s, 1H), 5.25 (d, *J* = 3.5 Hz, 1H), 4.97 (d, *J* = 2.7 Hz, 1H), 4.29 (q, *J* = 7.1 Hz, 2H), 3.77 (s, 3H), 3.57 (t, *J* = 3.2 Hz, 1H), 2.42 (s, 3H), 1.31 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.8, 158.1, 144.6, 143.7, 140.9, 134.6, 133.9, 132.7, 129.5, 129.0, 128.4, 128.0, 127.9, 125.3, 116.3, 113.5, 70.0, 61.0, 55.2, 52.7, 21.5, 14.2; HRMS-ESI calcd for C₂₉H₂₉NO₅S [M + Na]⁺ 526.1659, found 526.1663.

Ethyl trans-2-(3-(4-chlorophenyl)-5-phenyl-1-tosyl-2,3dihydro-1H-pyrrol-2-yl)acrylate (3c): yield 85%; white solid; mp 195–197 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.69 (dd, J = 6.3, 2.6 Hz, 2H), 7.45 (m, 3H), 7.26 (d, J = 3.4 Hz, 1H), 7.03 (d, J = 8.1 Hz, 2H), 6.98 (d, J = 8.3 Hz, 2H), 6.79 (d, J = 8.3 Hz, 2H), 6.51 (s, 1H), 6.30 (s, 1H), 5.29 (d, J = 3.5 Hz, 1H), 5.02 (s, 1H), 4.30 (q, J = 7.1 Hz, 2H), 3.57 (t, J = 2.8 Hz, 1H), 2.42 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 145.4, 144.2, 141.0, 140.3, 133.7, 132.4, 132.1, 129.4, 129.3, 128.7, 128.4, 128.2, 128.0, 127.8, 125.6, 115.3, 69.6, 61.2, 52.1, 21.5, 14.2; HRMS-ESI calcd for C₂₈H₂₆ClNO₄S [M + Na]⁺ 530.1163, found 530.1157.

Ethyl *trans*-2-(3-(4-fluorophenyl)-5-phenyl-1-tosyl-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3d): yield 97%; white solid; mp 183–185 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.69 (dd, *J* = 6.1, 2.5 Hz, 2H), 7.44 (m, 3H), 7.29 (d, *J* = 8.1 Hz, 2H), 7.06 (d, *J* = 8.0 Hz, 2H), 6.79–6.68 (m, 4H), 6.50 (s, 1H), 6.29 (s, 1H), 5.28 (d, *J* = 3.5 Hz, 1H), 4.99 (br s, 1H), 4.30 (q, *J* = 7.1 Hz, 2H), 3.59 (t, *J* = 2.9 Hz, 1H), 2.41 (s, 3H), 1.33 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 161.4 (d, *J* = 245.0 Hz), 145.1, 144.0, 140.6, 138.2 (d, *J* = 2.7 Hz), 133.8, 132.5, 129.5, 129.3, 129.0 (d, *J* = 7.9 Hz), 128.4, 127.93, 127.90, 125.5, 115.6, 114.8 (d, *J* = 21.1 Hz), 69.8, 61.1, 52.3, 21.5, 14.2; HRMS-ESI calcd for C₂₈H₂₆FNO₄S [M + Na]⁺ 514.1459, found 514.1450.

Ethyl *trans*-2-(5-phenyl-1-tosyl-3-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3e): yield 99%; white solid; mp 177–178 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.71 (m, 2H), 7.45 (m, 3H), 7.28 (s, 1H), 7.23 (s, 1H), 6.99 (d, *J* = 8.1 Hz, 4H), 6.53 (s, 1H), 6.34 (s, 1H), 5.32 (d, *J* = 3.6 Hz, 1H), 5.06 (s, 1H), 4.31 (q, *J* = 7.1 Hz, 2H), 3.65 (t, *J* = 2.8 Hz, 1H), 2.37 (s, 3H), 1.34 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 146.3, 145.8, 144.1, 140.3, 133.8, 132.3, 129.4, 128.40, 128.43 (q, *J* = 32.1 Hz), 128.3, 128.0, 127.8, 127.7, 125.7, 124.9 (q, *J* = 3.7 Hz), 124.2 (q, *J* = 272.0 Hz), 114.8, 69.4, 61.2, 52.4, 21.3, 14.2; HRMS-ESI calcd for C₂₉H₂₆F₃NO₄S [M + Na]⁺ 564.1427, found 564.1422.

Ethyl *trans*-2-(3-(3-nitrophenyl)-5-phenyl-1-tosyl-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3f): yield 94%; white solid; mp 197–199 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, *J* = 6.6 Hz, 1H), 7.75 (dd, *J* = 6.6, 2.8 Hz, 2H), 7.65 (d, *J* = 7.8 Hz, 1H), 7.59 (s, 1H), 7.48 (m, 3H), 7.32 (t, *J* = 7.9 Hz, 1H), 7.21 (d, *J* = 8.1 Hz, 2H), 6.93 (d, *J* = 8.1 Hz, 2H), 6.56 (s, 1H), 6.38 (s, 1H), 5.38 (d, *J* = 3.6 Hz, 1H), 5.10 (s, 1H), 4.33 (m, 2H), 3.70 (t, *J* = 2.8 Hz, 1H), 2.26 (s, 3H), 1.37 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 147.9, 146.6, 144.7, 144.1, 139.9, 134.3, 133.6, 132.1, 129.6, 129.4, 129.2, 128.5, 128.1, 127.6, 126.0, 122.1, 121.4, 113.8, 69.4, 61.4, 51.8, 21.3, 14.2; HRMS-ESI calcd for C₂₈H₂₆N₂O₆S [M + Na]⁺ 541.1404, found 541.1408.

Ethyl *trans*-2-(3-(furan-2-yl)-5-phenyl-1-tosyl-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3g): yield 87%; white solid; mp 122– 124 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.64 (m, 2H), 7.42 (m, 3H), 7.35 (d, *J* = 8.2 Hz, 2H), 7.12 (d, *J* = 8.0 Hz, 2H), 7.09 (s, 1H), 6.51 (s, 1H), 6.29 (s, 1H), 6.03 (m, 1H), 5.39 (d, *J* = 3.0 Hz, 1H), 5.25 (d, *J* = 3.6 Hz, 1H), 5.14 (br s, 1H), 4.30 (m, 2H), 3.64 (t, *J* = 3.0 Hz, 1H), 2.40 (s, 3H), 1.32 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.5, 154.2, 145.3, 143.6, 141.4, 140.1, 133.5, 132.3, 129.4, 129.2, 128.3, 128.0, 127.9, 125.7, 113.4, 109.9, 105.8, 67.2, 61.1, 47.2, 21.5, 14.1; HRMS-ESI calcd for C₂₆H₂₅NO₅S [M + Na]⁺ 486.1346, found 486.1345.

Ethyl *trans*-2-(5-(4-bromophenyl)-3-(4-chlorophenyl)-1tosyl-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3h): yield 88%; white solid; mp 231–232 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.57 (m, 4H), 7.25 (d, *J* = 8.4 Hz, 2H), 7.04 (d, *J* = 8.0 Hz, 2H), 6.97 (d, *J* = 8.4 Hz, 2H), 6.74 (d, *J* = 8.4 Hz, 2H), 6.50 (s, 1H), 6.24 (s, 1H), 5.31 (d, *J* = 3.6 Hz, 1H), 4.99 (br s, 1H), 4.30 (q, *J* = 7.1 Hz, 2H), 3.57 (t, *J* = 2.9 Hz, 1H), 2.43 (s, 3H), 1.33 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.7, 144.4, 144.6, 140.7, 140.2, 133.4, 132.2, 131.3, 131.2, 129.8, 129.5, 128.6, 128.2, 127.7, 125.6, 123.4, 115.9, 69.7, 61.2, 52.1, 21.5, 14.2; HRMS-ESI calcd for C₂₈H₂₅BrClNO₄S [M + Na]⁺ 608.0268, found 608.0261. Ethyl *trans*-2-(5-(4-bromophenyl)-3-(4-fluorophenyl)-1-tosyl-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3i): yield 84%; white solid; mp 233–234 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.56 (m, 4H), 7.28 (m, 2H), 7.07 (d, *J* = 8.0 Hz, 2H), 6.72 (m, 4H), 6.49 (s, 1H), 6.21 (s, 1H), 5.29 (d, *J* = 3.6 Hz, 1H), 4.96 (d, *J* = 2.7 Hz, 1H), 4.29 (q, *J* = 7.1 Hz, 2H), 3.59 (t, *J* = 3.2 Hz, 1H), 2.41 (s, 3H), 1.32 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.7, 161.5 (d, *J* = 245.4 Hz), 144.2, 144.1, 140.5, 137.9 (d, *J* = 2.8 Hz), 133.6, 131.4, 131.2, 129.9, 129.7, 128.9 (d, *J* = 7.8 Hz), 127.9, 125.5, 123.3, 116.2, 114.9 (d, *J* = 21.2 Hz), 69.9, 61.2, 52.4, 21.5, 14.2; HRMS-ESI calcd for C₂₈H₂₅BrFNO₄S [M + Na]⁺ 592.0564, found 592.0560.

Ethyl *trans*-2-(5-(4-chlorophenyl)-3-phenyl-1-tosyl-2,3dihydro-1*H*-pyrrol-2-yl)acrylate (3j): yield 96%; white solid; mp 209–210 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, *J* = 8.4 Hz, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 7.30 (d, *J* = 8.1 Hz, 2H), 7.14–7.00 (m, 5H), 6.68 (d, *J* = 7.4 Hz, 2H), 6.49 (s, 1H), 6.19 (s, 1H), 5.28 (d, *J* = 3.5 Hz, 1H), 4.98 (d, *J* = 3.0 Hz, 1H), 4.28 (m, 2H), 3.63 (t, *J* = 3.3 Hz, 1H), 2.41 (s, 3H), 1.30 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.7, 144.0, 143.8, 142.0, 140.8, 134.9, 133.4, 131.1, 129.6, 129.4, 129.1, 128.2, 128.0, 127.3, 126.4, 125.6, 116.6, 69.9, 61.1, 53.4, 21.6, 14.2; HRMS-ESI calcd for C₂₈H₂₆CINO₄S [M + Na]⁺ 530.1163, found 530.1159.

Ethyl *trans*-2-(5-(4-chlorophenyl)-1-tosyl-3-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3k): yield 89%; white solid; mp 211–212 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, *J* = 8.4 Hz, 2H), 7.42 (d, *J* = 8.4 Hz, 2H), 7.30–7.20 (m, 4H), 7.00 (d, *J* = 8.1 Hz, 2H), 6.95 (d, *J* = 8.1 Hz, 2H), 6.52 (s, 1H), 6.27 (s, 1H), 5.33 (d, *J* = 3.5 Hz, 1H), 5.04 (s, 1H), 4.31 (q, *J* = 7.1 Hz, 2H), 3.66 (s, 1H), 2.37 (s, 3H), 1.34 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.7, 146.1, 144.7, 144.3, 140.2, 135.3, 133.5, 130.7, 129.6, 129.5, 128.4 (q, *J* = 32.2 Hz), 128.3, 127.7, 127.6, 125.7, 125.0 (q, *J* = 3.6 Hz), 124.1 (q, *J* = 272.0 Hz), 115.3, 69.5, 61.2, 52.4, 21.3, 14.2; HRMS-ESI calcd for C₂₉H₂₅ClF₃NO₄S [M + Na]⁺ 598.1037, found 598.1036.

Ethyl *trans*-2-(5-(4-nitrophenyl)-3-phenyl-1-tosyl-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3*I*): yield 95%; white solid; mp 224–225 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.29 (d, *J* = 8.7 Hz, 2H), 7.85 (d, *J* = 8.7 Hz, 2H), 7.31 (d, *J* = 8.2 Hz, 2H), 7.13 (m, 3H), 7.03 (m, 2H), 6.64 (d, *J* = 7.4 Hz, 2H), 6.50 (s, 1H), 6.16 (s, 1H), 5.48 (d, *J* = 3.5 Hz, 1H), 4.93 (d, *J* = 3.4 Hz, 1H), 4.29 (m, 2H), 3.71 (t, *J* = 3.5 Hz, 1H), 2.43 (s, 3H), 1.30 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.5, 147.9, 144.4, 143.1, 141.5, 140.6, 139.2, 132.9, 129.8, 128.9, 128.3, 128.0, 127.3, 126.6, 125.9, 123.3, 119.7, 70.2, 61.2, 53.8, 21.6, 14.1; HRMS-ESI calcd for C₂₈H₂₆N₂O₆S [M + Na]⁺ 541.1404, found 541.1403.

Ethyl *trans*-2-(3-(4-chlorophenyl)-5-(4-nitrophenyl)-1-tosyl-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3m): 91% yield; white solid; mp 231–232 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.30 (d, *J* = 8.7 Hz, 2H), 7.86 (d, *J* = 8.7 Hz, 2H), 7.27 (d, *J* = 7.0 Hz, 2H), 7.09 (d, *J* = 8.0 Hz, 2H), 7.00 (d, *J* = 8.4 Hz, 2H), 6.71 (d, *J* = 8.4 Hz, 2H), 6.51 (s, 1H), 6.21 (s, 1H), 5.50 (d, *J* = 3.5 Hz, 1H), 4.97 (d, *J* = 2.3 Hz, 1H), 4.30 (q, *J* = 7.1 Hz, 2H), 3.66 (t, *J* = 3.0 Hz, 1H), 2.44 (s, 3H), 1.34 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.6, 148.1, 144.8, 143.6, 140.2, 140.1, 138.9, 133.0, 132.5, 129.7, 128.9, 128.6, 128.4, 127.8, 125.8, 123.4, 118.9, 69.9, 61.3, 52.6, 21.6, 14.2; HRMS-ESI calcd for C₂₈H₂₅ClN₂O₆S [M + Na]⁺ 575.1014, found 575.1012.

Ethyl *trans*-2-(3-(4-fluorophenyl)-5-(4-nitrophenyl)-1-tosyl-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3n): yield 84%; white solid; mp 203–205 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.29 (d, *J* = 8.8 Hz, 2H), 7.85 (d, *J* = 8.8 Hz, 2H), 7.30 (d, *J* = 8.3 Hz, 2H), 7.12 (d, *J* = 8.0 Hz, 2H), 6.71 (m, 4H), 6.50 (s, 1H), 6.19 (s, 1H), 5.48 (d, *J* = 3.6 Hz, 1H), 4.93 (d, *J* = 3.0 Hz, 1H), 4.30 (q, *J* = 7.1 Hz, 2H), 3.68 (t, *J* = 3.3 Hz, 1H), 2.43 (s, 3H), 1.33 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.6, 161.6 (d, *J* = 245.7 Hz) 148.0, 144.6, 143.3, 140.3, 139.0, 137.4 (d, *J* = 3.3 Hz), 133.1, 129.7, 128.94, 128.86 (d, *J* = 7.8 Hz), 127.9, 125.8, 123.3, 119.3, 115.0 (d, *J* = 21.3 Hz), 70.1, 61.2, 52.7, 21.5, 14.2; HRMS-ESI calcd for C₂₈H₂₅FN₂O₆S [M + Na]⁺ 559.1310, found 559.1313. Butyl *trans*-2-(3,5-diphenyl-1-tosyl-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (30): yield 94%; white solid; mp 131–132 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (m, 2H), 7.43 (m, 3H), 7.31 (d, *J* = 7.9 Hz, 2H), 7.06 (m, 5H), 6.71 (d, *J* = 7.6 Hz, 2H), 6.49 (s, 1H), 6.26 (s, 1H), 5.27 (d, *J* = 3.4 Hz, 1H), 5.00 (s, 1H), 4.30–4.05 (m, 2H), 3.61 (s, 1H), 2.40 (s, 3H), 1.68–1.59 (m, 2H), 1.38 (m, 2H), 0.93 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.8, 144.8, 143.8, 142.3, 141.0, 133.6, 132.6, 129.5, 129.1, 128.4, 128.1, 128.0, 127.9, 127.4, 126.2, 125.4, 116.0, 69.7, 64.9, 53.5, 30.5, 21.6, 19.2; 13.7; HRMS-ESI calcd for C₃₀H₃₁NO₄S [M + Na]⁺ 524.1866, found 524.1860.

tert-Butyl *trans*-2-(3,5-diphenyl-1-tosyl-2,3-dihydro-1*H*-pyrrol-2-yl)acrylate (3p): yield 90%; white solid; mp 93–95 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.67 (m, 2H), 7.41 (m, 3H), 7.33 (m, 2H), 7.10 (m, 3H), 7.02 (m, 2H), 6.68 (d, *J* = 7.5 Hz, 2H), 6.38 (s, 1H), 6.16 (s, 1H), 5.24 (s, 1H), 4.98 (s, 1H), 3.60 (s, 1H), 2.41 (s, 3H), 1.49 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 164.9, 144.8, 143.7, 142.5, 142.4, 133.6, 132.7, 129.5, 129.0, 128.4, 128.1, 128.1, 127.8, 127.4, 126.3, 124.4, 116.2, 81.5, 69. 7, 53.8, 28.0, 21.6; HRMS-ESI calcd for C₃₀H₃₁NO₄S [M + Na]⁺ 524.1866, found 524.1869.

Ethyl *trans*-2-(3-phenyl-1-tosyl-2,3,4,5-tetrahydro-1*H*-benzo[*g*]indol-2-yl)acrylate (3q): yield 83%; white solid; mp 142–144 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, *J* = 7.7 Hz, 1H), 7.37 (m, 4H), 7.23 (m, 1H), 7.13–7.06 (m, 3H), 6.99 (m, 2H), 6.54 (d, *J* = 7.4 Hz, 2H), 6.39 (s, 1H), 6.07 (s, 1H), 4.90 (d, *J* = 3.3 Hz, 1H), 4.21 (m, 2H), 3.42 (s, 1H), 2.91–2.70 (m, 2H), 2.44 (s, 3H), 2.12–1.89 (m, 2H), 1.21 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.7, 143.8, 141.1, 141.0, 138.0, 135.8, 132.9, 131.1, 129.6, 129.4, 129.1, 128.4, 128.2, 127.7, 127.6, 127.2, 126.3, 126.0, 125.4, 70.2, 61.00, 56.6, 29.3, 23.2, 21.6, 14.0; HRMS-ESI calcd for C₃₀H₂₉NO₄S [M + Na]⁺ 522.1709, found 522.1706.

Ethyl 4,5-diphenyl-3-(phenyl(tosylimino)methyl)cyclopent-1-enecarboxylate (4): A mixture of imine 1a (90 mg, 0.25 mmol), allylic carbonate 2e (93 mg, 0.3 mmol), and PhPMe₂ (8 μL, 0.05 mmol) in CH₂Cl₂ (2 mL) was stirred at room temperature for 24 h. Then the reaction mixture was concentrated on a rotary evaporator under reduced pressure and the residue was purified by column chromatography (eluted with petroleum ether—ethyl acetate 10:1) to afford the product 4 (90 mg) in 65% yield: colorless oil; ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, *J* = 8.1 Hz, 2H), 7.33 (d, *J* = 8.1 Hz, 2H), 7.27 (m, 1H), 7.19–7.09 (m, 7H), 7.08 (m, 3H), 6.92 (m, 2H), 6.85 (m, 2H), 6.79 (s, 1H), 4.46 (d, *J* = 8.0 Hz, 2H), 4.10–3.88 (m, 2H), 3.66 (m, 1H), 2.46 (s, 3H), 1.01 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 184.6, 163.9, 143.9, 143.5, 142.9, 141.9, 138.2, 137.5, 136.9, 130.9, 129.4, 128.6, 128.3, 127.8, 127.5, 127.4, 127.3, 127.2, 127.0, 126.4, 70.0, 60.2, 54.8, 53.9, 21.5, 13.8; HRMS-ESI calcd for C₃₄H₃₁NO₄S [M + H]⁺ 550.2047, found 550.2050.

ASSOCIATED CONTENT

Supporting Information. Copies of ¹H and ¹³C NMR spectra for **10**, **3**, and **4**, X-ray crystallographic data (CIF file), and an ORTEP drawing for **3a**. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: zhengjiehe@nankai.edu.cn.

ACKNOWLEDGMENT

Financial support from the National Natural Science Foundation of China (Grant Nos. 20872063 and 21072100) is gratefully acknowledged. The authors also thank Professor Qilin Zhou of Nankai University for his valuable advice in the preparation of this manuscript.

REFERENCES

(1) Bird, C. W.; Cheeseman, G. W. H. In *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R., Rees, C. W., Eds.; Pergamon: Oxford, UK, 1984; Vol. 4, p 89.

- (2) O'Hagan, D. Nat. Prod. Rep. 2000, 17, 435.
- (3) Butler, M. S. J. Nat. Prod. 2004, 67, 2141.
- (4) Walker, D.; Hiebert, J. D. Chem. Rev. 1967, 67, 153.

(5) Shim, Y. K.; Youn, J. I.; Chun, J. S.; Park, T. H.; Kim, M. H.; Kim, W. J. Synthesis 1990, 753.

(6) Le Quesne, P. W.; Dong, Y.; Blythe, T. A. Alkaloids: Chem. Biol. Perspect. 1999, 13, 237.

(7) Kidwai, M.; Venkataramanan, R.; Mohan, R.; Sapra, P. *Curr. Med. Chem.* **2002**, *9*, 1209.

(8) Magedov, I. V.; Luchetti, G.; Evdokimov, N. K.; Manpadi, M.; Steelant, W. F. A.; Van Slambrouck, S.; Tongwa, P.; Antipin, M. Y.; Kornienko, A. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 1392 and references cited therein.

(9) Bellina, F.; Rossi, R. Tetrahedron 2006, 62, 7213.

(10) Brichacek, M.; Njardarson, J. T. Org. Biomol. Chem. 2009, 7, 1761.

(11) Coldham, I.; Hufton, R. Chem. Rev. 2005, 105, 2765.

(12) Pandey, G.; Banerjee, P.; Gadre, S. Chem. Rev. 2006, 106, 4484.

(13) Lu, L.-Q.; Zhang, J.-J.; Li, F.; Cheng, Y.; An, J.; Chen, J.-R.; Xiao,

W.-J. Angew. Chem., Int. Ed. 2010, 49, 4495.

(14) Liu, C.-R.; Zhu, B.-H.; Zheng, J.-C.; Sun, X.-L.; Xie, Z.; Tang, Y. *Chem. Commun.* **2011**, *47*, 1342.

(15) Monge, D.; Jensen, K. L.; Franke, P. T.; Lykke, L.; Jorgensen, K. A. *Chem.—Eur. J.* **2010**, *16*, 9478.

(16) Fan, J.; Gao, L.; Wang, Z. *Chem. Commun.* **2009**, 5021 and references cited therein.

(17) Guo, C.; Xue, M.-X.; Zhu, M.-K.; Gong, L.-Z. Angew. Chem., Int. Ed. 2008, 47, 3414.

(18) Zhou, X.; Zhang, H.; Yuan, J.; Mai, L.; Li, Y. Tetrahedron Lett. 2007, 48, 7236.

(19) Wurz, R. P.; Charette, A. B. Org. Lett. 2005, 7, 2313.

(20) Ding, C.-H.; Dai, L.-X.; Hou, X.-L. Tetrahedron 2005, 61, 9586.

(21) Kinderman, S. S.; van Maarseveen, J. H.; Schoemaker, H. E.;

Hiemstra, H.; Rutjes, F. P. J. T. Org. Lett. 2001, 3, 2045.

(22) Busacca, C. A.; Dong, Y. Tetrahedron Lett. 1996, 37, 3947.

- (23) Zheng, J.-C.; Zhu, C.-Y.; Sun, X.-L.; Tang, Y.; Dai, L.-X. J. Org.
- Chem. 2008, 73, 6909 and references cited therein.
 - (24) Sun, X.-L.; Tang, Y. Acc. Chem. Res. 2008, 41, 937.

(25) Aggarwal, V. K.; Harvey, J. N.; Robiette, R. Angew. Chem., Int. Ed. 2005, 44, 5468.

(26) Riches, S. L.; Saha, C.; Filgueira, N. F.; Grange, E.; McGarrigle,

- E. M.; Aggarwal, V. K. J. Am. Chem. Soc. 2010, 132, 7626.
 - (27) Ye, L.-W.; Zhou, J.; Tang, Y. Chem. Soc. Rev. 2008, 37, 1140.
 - (28) Cowen, B. J.; Miller, S. J. Chem. Soc. Rev. 2009, 38, 3102.
 - (29) Xu, Z.; Lu, X. Tetrahedron Lett. 1997, 38, 3461.
 - (30) Zheng, S.; Lu, X. Org. Lett. 2008, 10, 4481.
 - (31) Schuler, M.; Duvvuru, D.; Retailleau, P.; Betzer, J.-F.; Marinetti,
- A. Org. Lett. 2009, 11, 4406 and references cited therein.
 (32) Zhu, X. F.; Lan, J.; Kwon, O. J. Am. Chem. Soc. 2003, 125, 4716.
 - (33) Chen, Z.; Zhang, J. Chem. Asian J. 2010, 5, 1542.
 - (34) Xie, P.; Huang, Y.; Chen, R. Org. Lett. 2010, 12, 3768.
 - (35) Zhou, R.; Wang, J.; Song, H.; He, Z. Org. Lett. 2011, 13, 580.
- (36) Zhou, R.; Wang, C.; Song, H.; He, Z. *Org. Lett.* **2010**, *12*, 976 and references cited therein.

(37) Similar hydrogen transfer processes were also proposed in the phosphine-catalyzed annulation reactions. See refs 32 and 33.

(38) Cai, L.; Zhang, B.; Wu, G.; Song, H.; He, Z. Chem. Commun. 2011, 47, 1045.

(39) Esquivias, J.; Arrayas, R. G.; Carretero, J. C. J. Am. Chem. Soc. 2007, 129, 1480.